Cost Effectiveness and Resource Allocation

Papers
(The H4-Index of Cost Effectiveness and Resource Allocation is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Vaccination distribution by community pharmacists under the COVID-19 vaccine appointment system in Taiwan61
Quantifying the direct cost benefits of vestibular telemetry using the CAVA system to diagnose the causes of dizziness45
Prescription cost analysis and economic impact of drug treatment in patients with chronic illness, attending the medicine out-patient department in a tertiary care hospital at South Delhi27
The use of cost-effectiveness analysis for health benefit package design – should countries follow a sectoral, incremental or hybrid approach?27
Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency26
Comparison of current relative value unit-based prices and utility between common surgical procedures, including orthopedic surgeries, in South Korea24
A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial23
Willingness to pay for cataract surgery and its associated factors in selected medical centers in Urmia, Iran22
Cost-effectiveness of implant movement analysis in aseptic loosening after hip replacement: a health-economic model21
Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value21
Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis20
Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in “Boao Lecheng Pilot Zone”20
Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia18
Cost-effectiveness analysis of coronary arteries bypass grafting (CABG) and percutaneous coronary intervention (PCI) through drug stent in iran: a comparative study15
Factor associated with willingness to pay for prevention of cancer: a study of prostate cancer screening15
Economic burden of knee joint replacement in Iran15
0.12117195129395